The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

As well as, falling in tandem with the release of Pfizer’s annual earnings report, which reflected revenues of $63.6 billion. In the announcement, Bourla stated: “I’m excited for what’s ...

Pfizer CEO Albert Bourla revealed to stakeholders this week that the rendezvous took place in December, a few weeks after RFK Jr was nominated to head the Department of Health and Human Services ...

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

Pfizer’s chief executive said he was “disappointed” with Robert F Kennedy Jr’s refusal to disavow the debunked link between vaccines and autism, even as he expressed confidence that the Trump ...

Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...